#VisualAbstract: Adjuvant PD-1 Blockade With Camrelizumab Improves Survival in Nasopharyngeal Carcinoma
Click here to read this study in JAMA. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in JAMA. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable ...
1. Camrelizumab improved the overall survival and the progression-free survival of esophageal squamous cell carcinoma patients compared to placebo treatment ...
Click to read the study in The Lancet Oncology.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.